J. M. Adams and S. Cory, The Bcl-2 Protein Family: Arbiters of Cell Survival, Science, vol.281, issue.5381, pp.1322-1326, 1998.
DOI : 10.1126/science.281.5381.1322

L. J. Beverly and H. E. Varmus, MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family, Oncogene, vol.13, issue.9, pp.1274-1279466, 2008.
DOI : 10.1038/onc.2008.466

L. J. Beverly, W. W. Lockwood, P. P. Shah, H. Erdjument?bromage, and H. Varmus, Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1, Proc. Natl. Acad. Sci. USA, pp.119-126, 2012.
DOI : 10.1073/pnas.1119167109

L. Bodet, P. Gomez?bougie, C. Touzeau, C. Dousset, G. Descamps et al., ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3910, 2011.
DOI : 10.1182/blood-2010-11-317438

N. D. Borson, M. Q. Lacy, and P. J. Wettstein, Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma, Blood, vol.100, issue.13, pp.4629-4639, 2002.
DOI : 10.1182/blood.V100.13.4629

K. L. Boylan, M. A. Gosse, S. E. Staggs, S. Janz, S. Grindle et al., A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma, Cancer Research, vol.67, issue.9, pp.4069-4078, 2007.
DOI : 10.1158/0008-5472.CAN-06-3699

D. R. Carrasco, G. Tonon, Y. Huang, Y. Zhang, R. Sinha et al., High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients, Cancer Cell, vol.9, issue.4, pp.313-325, 2006.
DOI : 10.1016/j.ccr.2006.03.019

D. R. Carrasco, K. Sukhdeo, M. Protopopova, R. Sinha, M. Enos et al., The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis, Cancer Cell, vol.11, issue.4, pp.349-360, 2007.
DOI : 10.1016/j.ccr.2007.02.015

M. Chesi, D. F. Robbiani, M. Sebag, W. J. Chng, M. Affer et al., AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies, Cancer Cell, vol.13, issue.2, pp.167-180, 2008.
DOI : 10.1016/j.ccr.2008.01.007

W. C. Cheung, J. S. Kim, M. Linden, L. Peng, B. Van-ness et al., Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice, Journal of Clinical Investigation, vol.113, issue.12, pp.1763-1773, 2004.
DOI : 10.1172/JCI20369DS1

J. O. Claudio, E. Masih?khan, H. Tang, J. Gonçalves, M. Voralia et al., A molecular compendium of genes expressed in multiple myeloma, Blood, vol.100, issue.6, pp.2175-2186, 2002.
DOI : 10.1182/blood-2002-01-0008

T. Cluzeau, G. Robert, N. Mounier, J. M. Karsenti, M. Dufies et al., BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients, Oncotarget, vol.3, issue.4, pp.490-501481, 2012.
DOI : 10.18632/oncotarget.481

D. Vos, J. , C. Bagnis, L. Bonnafoux, G. Requirand et al., Comparison of Murine Leukemia Virus, Human Immunodeficiency Virus, and Adeno-Associated Virus Vectors for Gene Transfer in Multiple Myeloma: Lentiviral Vectors Demonstrate a Striking Capacity to Transduce Low-Proliferating Primary Tumor Cells, Human Gene Therapy, vol.14, issue.18, pp.1727-1739, 2003.
DOI : 10.1089/104303403322611746

A. Enders, P. Bouillet, H. Puthalakath, Y. Xu, D. M. Tarlinton et al., Loss of the Pro-Apoptotic BH3-only Bcl-2 Family Member Bim Inhibits BCR Stimulation???induced Apoptosis and Deletion of Autoreactive B Cells, The Journal of Experimental Medicine, vol.160, issue.7, pp.1119-1126, 2003.
DOI : 10.4049/jimmunol.166.10.6025

S. F. Fischer, P. Bouillet, K. O. Donnell, A. Light, D. M. Tarlinton et al., Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells, Blood, vol.110, issue.12, pp.3978-3984, 2007.
DOI : 10.1182/blood-2007-05-091306

J. P. Gaillard, J. Liautard, B. Klein, and J. Brochier, Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines, European Journal of Immunology, vol.36, issue.12, pp.3332-3340, 1997.
DOI : 10.1002/eji.1830271232

Y. Gao, H. Kazama, and S. Yonehara, Bim regulates B-cell receptor-mediated apoptosis in the presence of CD40 signaling in CD40-pre-activated splenic B cells differentiating into plasma cells, International Immunology, vol.24, issue.5, pp.283-292, 2012.
DOI : 10.1093/intimm/dxr127

N. Giuliani, S. Colla, R. Sala, M. Moroni, M. Lazzaretti et al., Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease, Blood, vol.100, issue.13, pp.4615-4621, 2002.
DOI : 10.1182/blood-2002-04-1121

P. Gomez?bougie, R. Bataille, and M. Amiot, The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells, European Journal of Immunology, vol.379, issue.11, pp.3156-3164, 2004.
DOI : 10.1002/eji.200424981

Ø. Hjertner, T. Standal, M. Børset, A. Sundan, and A. Waage, Bone Disease in Multiple Myeloma, Medical Oncology, vol.23, issue.4, pp.431-441431, 2006.
DOI : 10.1385/MO:23:4:431

N. D. Huntington, V. Labi, A. Cumano, P. Vieira, A. Strasser et al., Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis in the absence of IL-7, International Immunology, vol.21, issue.6, pp.715-725, 2009.
DOI : 10.1093/intimm/dxp043

URL : https://hal.archives-ouvertes.fr/pasteur-00429029

S. Iida, P. H. Rao, M. Butler, P. Corradini, M. Boccadoro et al., Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma, Nature Genetics, vol.90, issue.2, pp.226-230, 1997.
DOI : 10.1126/science.275.5299.540

N. Inohara, T. S. Gourley, R. Carrio, M. Muñiz, J. Merino et al., Diva, a Bcl-2 Homologue that Binds Directly to Apaf-1 and Induces BH3-independent Cell Death, Journal of Biological Chemistry, vol.273, issue.49, pp.32479-32486, 1998.
DOI : 10.1074/jbc.273.49.32479

N. Ke, A. Godzik, and J. C. Reed, Bcl-B, a Novel Bcl-2 Family Member That Differentially Binds and Regulates Bax and Bak, Journal of Biological Chemistry, vol.276, issue.16, pp.12481-12484, 2001.
DOI : 10.1074/jbc.C000871200

B. Klein, K. Tarte, M. Jourdan, K. Mathouk, J. Moreaux et al., Survival and Proliferation Factors of Normal and Malignant Plasma Cells, International Journal of Hematology, vol.276, issue.2, pp.106-113, 2003.
DOI : 10.1007/BF02983377

URL : https://hal.archives-ouvertes.fr/inserm-00130900

M. Krajewska, S. Kitada, J. N. Winter, D. Variakojis, A. Lichtenstein et al., Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies, Clinical Cancer Research, vol.14, issue.10, pp.3011-3021, 2008.
DOI : 10.1158/1078-0432.CCR-07-1955

M. Linden, N. Kirchhof, C. Carlson, and B. Van-ness, Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies, Blood, vol.103, issue.7, pp.2779-2786, 2004.
DOI : 10.1182/blood-2003-10-3399

F. Luciano, M. Krajewska, P. Ortiz?rubio, S. Krajewski, D. Zhai et al., Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma, Blood, vol.109, issue.9, pp.3849-3855, 2007.
DOI : 10.1182/blood-2006-11-056879

H. Ludwig, M. Beksac, J. Bladé, M. Boccadoro, J. Cavenagh et al., Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective, The Oncologist, vol.15, issue.1, pp.6-25, 2009.
DOI : 10.1634/theoncologist.2009-0203

A. Mansour, A. Anginot, S. J. Mancini, C. Schiff, G. F. Carle et al., Osteoclast activity modulates B-cell development in the bone marrow, Cell Research, vol.95, issue.7, pp.1102-1115, 2011.
DOI : 10.1359/jbmr.1997.12.9.1335

URL : https://hal.archives-ouvertes.fr/hal-00608176

T. J. Mcdonnell and S. J. Korsmeyer, Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18), Nature, vol.349, issue.6306, pp.254-256, 1991.
DOI : 10.1038/349254a0

A. A. Morales, M. Kurtoglu, S. M. Matulis, J. Liu, D. Siefker et al., Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, vol.118, issue.5, pp.1329-1339, 2011.
DOI : 10.1182/blood-2011-01-327197

N. Morito, K. Yoh, A. Maeda, T. Nakano, A. Fujita et al., A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23), Cancer Research, vol.71, issue.2, pp.339-348, 2011.
DOI : 10.1158/0008-5472.CAN-10-1057

H. Ohguchi, T. Hideshima, M. K. Bhasin, G. T. Gorgun, L. Santo et al., The KDM3A???KLF2???IRF4 axis maintains myeloma cell survival, Nature Communications, vol.157, p.10258, 2016.
DOI : 10.1128/MCB.02154-07

P. M. Oliver, T. Vass, J. Kappler, and P. Marrack, Loss of the proapoptotic protein, Bim, breaks B cell anergy, The Journal of Experimental Medicine, vol.142, issue.3, pp.731-741, 2006.
DOI : 10.1084/jem.186.11.1923

A. Palumbo and K. Anderson, Multiple Myeloma, New England Journal of Medicine, vol.364, issue.11, pp.1046-1060, 2011.
DOI : 10.1056/NEJMra1011442

URL : https://hal.archives-ouvertes.fr/hal-01282339

S. S. Park, J. S. Kim, L. Tessarollo, J. D. Owens, L. Peng et al., Insertion of c-Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice, Cancer Research, vol.65, issue.4, pp.1306-1315, 2005.
DOI : 10.1158/0008-5472.CAN-04-0268

G. J. Rautureau, M. Yabal, H. Yang, D. C. Huang, M. Kvansakul et al., The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist, Cell Death and Disease, vol.3, issue.12, 2012.
DOI : 10.1016/j.molcel.2005.02.003

M. Romagnoli, C. Séveno, S. Wuillème?toumi, M. Amiot, R. Bataille et al., The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma, British Journal of Haematology, vol.83, issue.2, pp.180-189, 2009.
DOI : 10.1111/j.1365-2141.2009.07608.x

R. W. Rooswinkel, B. Van-de-kooij, E. De-vries, M. Paauwe, R. Braster et al., Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity, Blood, vol.123, issue.18, pp.2806-2815, 2014.
DOI : 10.1182/blood-2013-08-519470

A. L. Shaffer, N. C. Emre, L. Lamy, V. N. Ngo, G. Wright et al., IRF4 addiction in multiple myeloma, Nature, vol.403, issue.7201, pp.226-231, 2008.
DOI : 10.1038/nature07064

H. Spets, T. Strömberg, P. Georgii?hemming, J. Siljason, K. Nilsson et al., Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells. Regulation during interleukin-6 (IL-6)-induced growth and survival, European Journal of Haematology, vol.56, issue.2, pp.76-89, 2002.
DOI : 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O

A. C. Sprynski, D. Hose, L. Caillot, T. Réme, J. D. Shaughnessy-jr et al., The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor, Blood, vol.113, issue.19, pp.4614-4626, 2009.
DOI : 10.1182/blood-2008-07-170464

URL : https://hal.archives-ouvertes.fr/inserm-00367812

M. Strobeck, Multiple myeloma therapies, Nature Reviews Drug Discovery, vol.30, issue.3, pp.181-182, 2007.
DOI : 10.1038/nrd2269

Y. Tu, S. Renner, F. Xu, A. Fleishman, J. Taylor et al., BCL?X expression in multiple my? eloma: possible indicator of chemoresistance, Cancer Res, vol.58, pp.256-262, 1998.

B. Van-de-kooij, R. W. Rooswinkel, F. Kok, M. Herrebout, E. De-vries et al., Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B, Oncogene, vol.49, issue.48, pp.5439-5448, 2013.
DOI : 10.1038/onc.2013.99

S. Wuillème?toumi, N. Robillard, P. Gomez, P. Moreau, S. L. Gouill et al., Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.96, issue.7, pp.1248-1252, 2005.
DOI : 10.1093/jnci/djh122

D. Zhai, N. Ke, H. Zhang, U. Ladror, M. Joseph et al., Characterization of the anti-apoptotic mechanism of Bcl-B, Biochemical Journal, vol.376, issue.1, pp.229-236, 2003.
DOI : 10.1042/bj20030374

P. Zhou, N. B. Levy, H. Xie, L. Qian, C. Y. Lee et al., MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes, Blood, vol.97, issue.12, pp.3902-3909, 2001.
DOI : 10.1182/blood.V97.12.3902